Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant

Eick-Cost, Angelia A; Ying, Saixia; Wells, Natalie

doi:10.1001/jamanetworkopen.2022.8071

Cited by 16 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the period of the pre-Delta variants, the effectiveness of both mRNA vaccines in protecting adults against symptomatic infection were excellent, i.e., around 89-95%. 78,110,111 Similar to Ad26.COV2.S and most likely other available vaccines, a reduction in the effectiveness of both mRNA vaccines against COVID-19 illness was observed during the wave of the Delta variant. 111,112 Both mRNA vaccines had relatively favorable safety profiles with common adverse events, such as soreness at the injection site, fever, fatigue, chills, and headache.…”

Section: Performances Of the Approved Covid-19 Vaccinesmentioning

confidence: 82%

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

Vidian¹,

Dikson²,

Litanto³

et al. 2022

Explor Res Hypothesis Med

View full text Add to dashboard Cite

The world is now in the third year of the COVID-19 pandemic. As such, enormous volumes of virological, immunological, and epidemiological knowledge pertaining to the SARS-CoV-2 infection have been obtained during these years. The SARS-CoV-2 Omicron variant is currently causing the latest wave of infection globally presumably due to its ability to transmit with ease among individuals and to escape from the existing neutralizing antibodies. Fortunately, numerous treatment agents as well as prophylactic vaccines are now available, thus providing people with a better chance to control this infectious disease. This review will discuss the Omicron variant of concern as well as the available treatments and vaccines for COVID-19.

show abstract

Section: Performances Of the Approved Covid-19 Vaccinesmentioning

confidence: 82%

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

Vidian¹,

Dikson²,

Litanto³

et al. 2022

Explor Res Hypothesis Med

View full text Add to dashboard Cite

show abstract

“…Twelve reviews were excluded from the 77 studies, 21 studies lacked sufficient data, two studies were related to inactivated vaccine, 58,59 and two studies were duplicated 24,60 . Finally, 40 studies out of total 1043 abstracts were finally included in our meta‐analysis, 16–54,60 involving 62 954 861 participates and two kinds of COVID‐19 mRNA vaccines, namely BNT162b2 and mRNA‐1273; two kinds of viral vector vaccines, namely ChAdOx1 and Ad26. COV2.S.…”

Section: Resultsmentioning

confidence: 99%

Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysis

Zhang

Yang

Huang

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

We assessed the effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants. Systematic search of PubMed, EMBASE, and CNKI (China National Knowledge Infrastructure) databases without language restriction for studies published before September 19, 2022. The review was registered with PROSPERO (CRD42022335430) and reported according to PRISMA guidelines. Forty studies met the inclusion criteria for this study, with 62 954 861 participants. The overall vaccine effectiveness (VE) to prevent COVID-19 infection was 0.76 (95% confidence interval [CI] 0.73-0.78), symptomatic infection was 0.87 (95% CI 0.83-0.91), hospital admissions was 0.82 (95% CI 0.75-0.87), and mortality was 0.76 (95% CI 0.48-0.89). Subgroup analysis were performed to characterize the effectiveness of different vaccines. When SARS-CoV-2 variants are taking account, the VE decreased along with the variation of the virus by clinical outcomes and vaccine types. The findings of this systematic review provide the best available evidence that BNT162b2, mRNA-1273, ChAdOx1, and Ad26. COV2.S seems to be approximately effective from predelta to omicron, but only modestly effective in participants aged 65 or older. When SARS-CoV-2 variants are taking account, VE decreased along with the variation of the virus for all mRNA and viral-vector vaccines.

show abstract

“…Submit your Manuscript | www.austinpublishinggroup.com because the only way to locate the cases of intradomiciliary infection using the analysis of the electronic home addresses made available by the families in the banks during the screening [47].…”

Section: Data Availabilitymentioning

confidence: 99%

Genomic Surveillance of SARS-CoV-2: Study of Cases Intradomiciliary Infection in Brazilian Amazonia

KS¹,

Sgorlon²,

AM³

et al. 2022

austinjinfectdis

View full text Add to dashboard Cite

Studies have shown that the family environment is very favorable for SARSCOV- 2 transmission, making family groups susceptible to intra-household infection because they maintain direct contact with an infected person. We screened a cohort of 416 individuals who tested positive for SARS-CoV-2 from June to October 2021 for intradomiciliary infection. Twenty-two families with an average of 2 to 4 members were located in 12 municipalities in the state of Rondônia. Nasopharyngeal samples were collected, extracted using the QIAamp viral RNA mini kit and genomic sequencing was performed using samples with ct<25 by Illumina platform, the sequences were analyzed for phylogeny, mutations, and lineages. Among the samples analyzed 72.72% matched for VOC Delta and 27.27% for Gamma variant. The median viral load for both variants was 6.95. The main symptoms presented were cough, headache, and fever. No hospitalizations or deaths were reported. We observed that among the positive individuals, 24% were immunized with the 1st and 2nd dose, 40% were partially immunized, and 36% were not immunized. For each strain, subvariants were identified, being P.1.4 and P.1.14 for the Gamma variant and AY.43, AY.99.2 and AY.122 for Delta. The mutations mostly behaved as lineage-defining, with only eight families showing point mutations. In conclusion, it was observed that despite the low adherence to immunization, household cases were equally expressed in viral characteristics and in the low rate of hospital evolution for COVID-19, and this may be a factor associated with the permanence of infection in an isolated family environment.

show abstract

Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant

Abstract: This case-control study evaluates the effectiveness of 3 COVID-19 vaccines for infection and hospitalization outcomes among US military personnel before and during the predominance of the Delta variant in the US.

Cited by 16 publications

References 30 publications

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysis

Genomic Surveillance of SARS-CoV-2: Study of Cases Intradomiciliary Infection in Brazilian Amazonia

Contact Info

Product

Resources

About